VIVS — VivoSim Labs, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1497253 ·
Last close
$0.12
Market Cap
$2.44M
52W High
$3.40
52W Low
$0.12
ADV30
1,118,087
Next earnings
—
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and build functional 3D human tissues through its proprietary technologies that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. has a strategic collaboration agreement with Chemveda Life Sciences to test and screen AI-derived drug compounds. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 18,000 — -2,759,000 -1,338,000 3,847,000 1,670,000 6,193,000
Mar 2026 40,000 40,000 -3,187,000 -5,764,000 7,386,000 5,024,000 8,485,000
Dec 2025 26,000 26,000 -2,750,000 -2,691,000 6,960,000 4,288,000 2,519,000
Sep 2025 28,000 28,000 -2,635,000 -2,545,000 9,686,000 6,677,000 2,621,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-10,100,000
Investing CF
$71,000
Financing CF
$2,644,000
CapEx
$-23,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.40
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-357,338,000
Inventory
$0
Receivables
$1,045,000
ST Investments
—
EBIT TTM
$-12,321,000
Pretax Income TTM
$-12,333,000
Interest Exp TTM
$12,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$112,000
EBITDA
$-11,137,000
Free Cash Flow
$-7,575,375
Enterprise Value
$693,899
Total Cash
$1,670,000
Total Debt
$316,000
Shares Out
20,281,495
Trailing EPS
$-4.47
Book Value
$-0.38
ROE
-343.1%
ROA
-89.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 131,000 -11,487,000 -13,843,000 7,390,000 8,485,000 -1,099,000 -10,827,000
Mar 2025 144,000 -12,616,000 -2,488,000 14,700,000 4,158,000 10,492,000 -9,461,000
Mar 2024 109,000 -15,086,000 -14,671,000 6,350,000 2,748,000 3,601,000 -14,653,000
Mar 2023 370,000 -17,731,000 -17,259,000 20,313,000 4,984,000 15,329,000 -12,408,000
Mar 2022 — — — — — — —

TTM Snapshot

Revenues TTM
$112,000
NetIncome TTM
$-12,338,000
OpCashFlow TTM
—
Assets (Latest)
$3,847,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
ABPO Abpro Holdings, Inc. $2.65M $0.45 —
CLDI Calidi Biotherapeutics, Inc. $2.06M $0.56 —
BCAB BioAtla, Inc. $3.00M $1.80 —
SNTI Senti Biosciences Holdings, Inc. $3.02M $0.10 —
CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. $3.62M $0.48 —

News headlines (Yahoo Finance, 1h cache)

VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting
2026-11-16 13:05 · Yahoo
VivoSim: Fiscal Q2 Earnings Snapshot
2026-11-12 23:09 · Yahoo
VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting
2026-11-10 13:05 · Yahoo
VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test
2026-11-03 13:05 · Yahoo
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
2026-10-21 12:05 · Yahoo
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
2026-10-07 12:05 · Yahoo
VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)
2026-07-21 14:28 · Yahoo
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
2026-07-21 12:05 · Yahoo
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
2026-07-16 12:30 · Yahoo
VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth
2026-07-15 14:46 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.